000281348 001__ 281348
000281348 005__ 20251012002027.0
000281348 0247_ $$2doi$$a10.1177/17474930251365861
000281348 0247_ $$2pmid$$apmid:40721902
000281348 0247_ $$2ISSN$$a1747-4930
000281348 0247_ $$2ISSN$$a1747-4949
000281348 0247_ $$2altmetric$$aaltmetric:179749924
000281348 037__ $$aDZNE-2025-01095
000281348 041__ $$aEnglish
000281348 082__ $$a610
000281348 1001_ $$aCordonnier, Charlotte$$b0
000281348 245__ $$aDiagnosis and management of cerebral amyloid angiopathy: a scientific statement from the International CAA Association and the World Stroke Organization.
000281348 260__ $$aLondon$$bSage$$c2025
000281348 3367_ $$2DRIVER$$aarticle
000281348 3367_ $$2DataCite$$aOutput Types/Journal article
000281348 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1759825406_17320$$xReview Article
000281348 3367_ $$2BibTeX$$aARTICLE
000281348 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000281348 3367_ $$00$$2EndNote$$aJournal Article
000281348 520__ $$aCerebral amyloid angiopathy (CAA) is a well-recognized and challenging disease for neurologists and other clinicians caring for the rapidly aging worldwide population. CAA is a major cause of spontaneous lobar intracerebral hemorrhage (ICH), and can also cause transient focal neurological episodes, and convexity subarachnoid hemorrhage, CAA-associated ICH has a high mortality, morbidity, and recurrence rate. CAA can affect a wide range of clinical decisions including use of antithrombotic medications, safety for anti-β-amyloid peptide (Aβ) immunotherapy, and need for anti-inflammatory or immunosuppressive treatment. We present guidelines, intended to inform the approach to individuals with suspected CAA, written on behalf of the International CAA Association and the World Stroke Organization (WSO). We cover five areas selected for their relevance to practice: (1) diagnosis, testing, and prediction of intracerebral hemorrhage risk; (2) antithrombotic agents and vascular interventions; (3) vascular risk factors and concomitant medications; (4) treatment of CAA manifestations; and (5) diagnosis and treatment of CAA-related inflammation and vasculitis. The statement has been reviewed and approved by the Executive Committee of the WSO, and the International CAA Association.
000281348 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000281348 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000281348 650_7 $$2Other$$aMRI
000281348 650_7 $$2Other$$aantithrombotic
000281348 650_7 $$2Other$$abrain bleed
000281348 650_7 $$2Other$$abrain microbleeds
000281348 650_7 $$2Other$$acerebral hemorrhage
000281348 650_7 $$2Other$$aleukoaraiosis
000281348 650_7 $$2NLM Chemicals$$aFibrinolytic Agents
000281348 650_2 $$2MeSH$$aHumans
000281348 650_2 $$2MeSH$$aCerebral Amyloid Angiopathy: diagnosis
000281348 650_2 $$2MeSH$$aCerebral Amyloid Angiopathy: therapy
000281348 650_2 $$2MeSH$$aCerebral Amyloid Angiopathy: complications
000281348 650_2 $$2MeSH$$aDisease Management
000281348 650_2 $$2MeSH$$aCerebral Hemorrhage: etiology
000281348 650_2 $$2MeSH$$aCerebral Hemorrhage: therapy
000281348 650_2 $$2MeSH$$aCerebral Hemorrhage: diagnosis
000281348 650_2 $$2MeSH$$aStroke: therapy
000281348 650_2 $$2MeSH$$aStroke: diagnosis
000281348 650_2 $$2MeSH$$aRisk Factors
000281348 650_2 $$2MeSH$$aFibrinolytic Agents: therapeutic use
000281348 650_2 $$2MeSH$$aSocieties, Medical
000281348 7001_ $$aKlijn, Catharina$$b1
000281348 7001_ $$00000-0003-3956-1668$$aSmith, Eric Edward$$b2
000281348 7001_ $$00000-0002-2108-9222$$aAl-Shahi Salman, Rustam$$b3
000281348 7001_ $$aChwalisz, Bart K$$b4
000281348 7001_ $$avan Etten, Ellis$$b5
000281348 7001_ $$aMuir, Ryan T$$b6
000281348 7001_ $$00000-0002-3385-3224$$aPiazza, Fabrizio$$b7
000281348 7001_ $$0P:(DE-2719)2812631$$aSchreiber, Stefanie$$b8
000281348 7001_ $$00000-0002-7815-0207$$aSchreuder, Floris Hbm$$b9
000281348 7001_ $$aSelim, Magdy$$b10
000281348 7001_ $$00000-0002-2802-1626$$aShoamanesh, Ashkan$$b11
000281348 7001_ $$aViswanathan, Anand$$b12
000281348 7001_ $$aWermer, Marieke$$b13
000281348 7001_ $$aZandi, Michael$$b14
000281348 7001_ $$00000-0001-5891-337X$$aCharidimou, Andreas$$b15
000281348 7001_ $$aGreenberg, Steven M$$b16
000281348 7001_ $$00000-0003-2074-1861$$aWerring, David$$b17
000281348 773__ $$0PERI:(DE-600)2211666-7$$a10.1177/17474930251365861$$gVol. 20, no. 8, p. 949 - 967$$n8$$p949 - 967$$tInternational journal of stroke$$v20$$x1747-4930$$y2025
000281348 8564_ $$uhttps://pub.dzne.de/record/281348/files/DZNE-2025-01095%20SUP.docx
000281348 8564_ $$uhttps://pub.dzne.de/record/281348/files/DZNE-2025-01095.pdf$$yOpenAccess
000281348 8564_ $$uhttps://pub.dzne.de/record/281348/files/DZNE-2025-01095%20SUP.doc
000281348 8564_ $$uhttps://pub.dzne.de/record/281348/files/DZNE-2025-01095%20SUP.odt
000281348 8564_ $$uhttps://pub.dzne.de/record/281348/files/DZNE-2025-01095%20SUP.pdf
000281348 8564_ $$uhttps://pub.dzne.de/record/281348/files/DZNE-2025-01095.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000281348 909CO $$ooai:pub.dzne.de:281348$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000281348 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812631$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000281348 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000281348 9141_ $$y2025
000281348 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-27
000281348 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-27
000281348 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000281348 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-27
000281348 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J STROKE : 2022$$d2024-12-27
000281348 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-27
000281348 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-27
000281348 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000281348 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-27
000281348 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J STROKE : 2022$$d2024-12-27
000281348 915__ $$0StatID:(DE-HGF)0430$$2StatID$$aNational-Konsortium$$d2024-12-27$$wger
000281348 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-27
000281348 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-27
000281348 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-27
000281348 9201_ $$0I:(DE-2719)1310010$$kAG Schreiber$$lMixed Cerebral Pathologies and Cognitive Aging$$x0
000281348 980__ $$ajournal
000281348 980__ $$aVDB
000281348 980__ $$aUNRESTRICTED
000281348 980__ $$aI:(DE-2719)1310010
000281348 9801_ $$aFullTexts